2016
DOI: 10.1111/bph.13532
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic potential of NADPH oxidase 1/4 inhibitors

Abstract: This article is part of a themed section on Redox Biology and Oxidative Stress in Health and Disease. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.12/issuetoc.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
135
0
5

Year Published

2017
2017
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 130 publications
(141 citation statements)
references
References 216 publications
1
135
0
5
Order By: Relevance
“…Unlike with NOX2 inhibition, little immunosuppression is observed and no spontaneous pathologies are found upon NOX4 inhibition or deletion (Aoyama et al, 2012). Moreover, it has progressed to clinical trials, showing great promise (Teixeira et al, 2016). …”
Section: Potential Treatments On Nox Activationmentioning
confidence: 99%
“…Unlike with NOX2 inhibition, little immunosuppression is observed and no spontaneous pathologies are found upon NOX4 inhibition or deletion (Aoyama et al, 2012). Moreover, it has progressed to clinical trials, showing great promise (Teixeira et al, 2016). …”
Section: Potential Treatments On Nox Activationmentioning
confidence: 99%
“…Thus, a rigorously developed ROS assay is critical for monitoring of enzyme activity and assessing the effects of putative Nox inhibitors. However, only a limited number of Nox inhibitors are currently available [37,38]. We propose that one of the reasons for the slow progress is the lack of availability of specific and selective ROS assays.…”
Section: Opportunities In Nox Inhibitor Discoverymentioning
confidence: 99%
“…This specific Nox1 and Nox4 inhibitor has a K i from 100 to 150 nM in cell‐free assays, does not inhibit other isoforms of Nox, xanthene oxidase, or the neutrophil oxidative burst, does not scavenge ROS, and has been previously shown to reverse fibrosis and improve survival in a mouse model of idiopathic pulmonary fibrosis . Nox4 is also a potential therapeutic target in pre‐clinical models of disease in many other systems including the liver, kidney, brain, bone, skin, cardiovascular system, gastrointestinal tract, and eye, and several forms of cancer …”
mentioning
confidence: 99%